Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Earnings & Estimates

USA - Nasdaq - NASDAQ:XENE - CA98420N1050 - Common Stock

39.98 USD
-0.76 (-1.87%)
Last: 1/16/2026, 8:00:02 PM
39.5 USD
-0.48 (-1.2%)
Pre-Market: 1/20/2026, 4:00:13 AM

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
XENE revenue by date.XENE revenue by date.
32.17M
371.01%
18.44M
-42.68%
9.43M
-48.86%
2.11M
-100.00%
300.002K7.682M5.1M
-33.61%
89.043M
1,645.94%
361.58M
306.07%
696.75M
92.70%
1.069B
53.43%
1.362B
27.41%
1.739B
27.68%
2.018B
16.04%
EBITDA
YoY % growth
XENE ebitda by date.XENE ebitda by date.
-30.66M
27.67%
-78.08M
-154.66%
-127.52M
-63.32%
-214.333M
-66.24%
-279.2M
-30.54%
-368.815M
-33.27%
-413.2M
-12.03%
-325.543M
21.21%
-286.875M
11.88%
-56.284M
80.38%
N/AN/AN/AN/A
EBIT
YoY % growth
XENE ebit by date.XENE ebit by date.
-31.3M
26.90%
-78.99M
-152.36%
-129.14M
-63.49%
-218.198M
-65.75%
-280.316M
-30.48%
-368.037M
-31.77%
-421.513M
-14.53%
-412.994M
2.02%
-195.375M
52.69%
96.896M
149.59%
386.75M
299.14%
598.25M
54.69%
870.36M
45.48%
1.04B
19.49%
Operating Margin
XENE operating margin by date.XENE operating margin by date.
-97.30%-428.36%-1,369.46%-10,341.13%-93,437.77%-4,790.90%-8,264.97%-463.81%-54.03%13.91%36.18%43.92%50.05%51.54%
EPS
YoY % growth
XENE eps by date.XENE eps by date.
-0.81
47.40%
-1.77
-118.52%
-2.04
-15.25%
-2.91
-33.33%
-3.17
-11.03%
-4.33
-43.23%
-4.81
-11.15%
-4.61
4.12%
-3.27
29.05%
-0.38
88.44%
2.29
705.77%
4.40
92.16%
7.05
60.13%
8.48
20.34%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth
-1.21
-44.19%
-1.15
-38.74%
-1.20
-12.17%
-1.25
-8.46%
-1.32
-8.81%
-1.35
-16.92%
-1.44
-19.83%
-1.41
-12.85%
-1.40
-6.04%
Revenue
Q2Q % growth

-100.00%
N/AN/AN/AN/A
EBITDA
Q2Q % growth
-99.065M
-32.23%
-94.347M
-30.89%
-97.663M
-5.08%
-102.21M
-8.27%
N/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-101.89M
-31.51%
-99.93M
-37.38%
-103.017M
-9.33%
-108.788M
-12.93%
-117.862M
-15.68%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2025
Q2Q % growth
-1.15
-41.98%
-1.180.032.13%
Q2 2025
Q2Q % growth
-1.07
-42.67%
-1.01-0.06-5.82%
Q1 2025
Q2Q % growth
-0.83
-33.87%
-0.930.1010.75%
Q4 2024
Q2Q % growth
-0.84
-31.25%
-0.880.044.31%
Q3 2024
Q2Q % growth
-0.81
-10.96%
-0.830.022.60%
Q2 2024
Q2Q % growth
-0.75
-4.17%
-0.71-0.04-5.10%
Q1 2024
Q2Q % growth
-0.62
1.59%
-0.680.068.49%
Q4 2023
Q2Q % growth
-0.64
-12.28%
-0.770.1317.35%
Q3 2023
Q2Q % growth
-0.73
-28.07%
-0.790.067.55%
Q2 2023
Q2Q % growth
-0.72
-30.91%
-0.71-0.01-1.23%
Q1 2023
Q2Q % growth
-0.63
-80.00%
-0.630.000.64%
Q4 2022
Q2Q % growth
-0.57
-18.75%
-0.600.034.45%
Q3 2022
Q2Q % growth
-0.57
-58.33%
-0.53-0.04-8.16%
Q2 2022
Q2Q % growth
-0.55
-7.84%
-0.49-0.06-11.64%
Q1 2022
Q2Q % growth
-0.35
16.67%
-0.410.0615.39%
Q4 2021
Q2Q % growth
-0.48
-41.18%
-0.38-0.10-26.96%
Q3 2021
Q2Q % growth
-0.36
-44.00%
-0.390.037.93%
Q2 2021
Q2Q % growth
-0.51 -0.49-0.02-4.44%
Q1 2021
Q2Q % growth
-0.42
-90.91%
-0.440.024.79%
Q4 2020
Q2Q % growth
-0.34 -0.410.0716.61%
Q3 2020
Q2Q % growth
-0.25 -0.15-0.10-61.86%
Q2 2020
Q2Q % growth
0.00 -0.240.24100.00%
Q1 2020
Q2Q % growth
-0.22 -0.330.1133.06%
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 -4 6 8
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2025
Q2Q % growth
7.5M 1.129M6.371M564.30%
Q4 2024
Q2Q % growth
339.997K-339.997K-100.00%
Q4 2023
Q2Q % growth
1.93M-1.93M-100.00%
Q3 2023
Q2Q % growth

-100.00%
1.479M-1.479M-100.00%
Q2 2023
Q2Q % growth

-100.00%
408K-408K-100.00%
Q1 2023
Q2Q % growth

-100.00%
582.859K-582.859K-100.00%
Q4 2022
Q2Q % growth

-100.00%
2.329M-2.329M-100.00%
Q3 2022
Q2Q % growth
130K
-98.40%
3.079M-2.949M-95.78%
Q2 2022
Q2Q % growth
540K
-75.68%
3.626M-3.086M-85.11%
Q1 2022
Q2Q % growth
8.77M
101.15%
8.874M-104K-1.17%
Q4 2021
Q2Q % growth
3.74M
-27.38%
5.075M-1.335M-26.31%
Q3 2021
Q2Q % growth
8.12M
23.97%
10.43M-2.31M-22.15%
Q2 2021
Q2Q % growth
2.22M
-83.41%
2.375M-155K-6.53%
Q1 2021
Q2Q % growth
4.36M
-38.42%
3.026M1.334M44.08%
Q4 2020
Q2Q % growth
5.15M 3.28M1.87M57.01%
Q3 2020
Q2Q % growth
6.55M 10.257M-3.707M-36.14%
Q2 2020
Q2Q % growth
13.38M 7.037M6.343M90.14%
Q1 2020
Q2Q % growth
7.08M 4.59M2.49M54.25%
XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 1.87% 0% 0.2%
RevenueN/A N/A 0% 0.03%